Compound Evidence File
#EC-2026-0732
Salbutamol
Filed under Oral Tablets. The bureau holds 140 laboratory returns for this compound from 47 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
47 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 22 Dec 2025 | 20 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 25 Feb 2026 | 16 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Jan 2026 | 22 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Dec 2025 | 27 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 3 May 2026 | 17 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Feb 2026 | 6 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Jan 2026 | 17 Mar 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Nov 2025 | 14 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Nov 2025 | 13 Jan 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Feb 2026 | 22 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 22 Apr 2026 | 3 May 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 10.0 | 10.0 | 10.0 | 3 Jul 2025 | 3 Jul 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Feb 2026 | 2 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 22 Apr 2026 | 4 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Dec 2025 | 5 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Apr 2026 | 10 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Jun 2026 | 18 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 28 May 2026 | 14 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 10.0 | 7 May 2026 | 11 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 9.9 | 9.9 | 10.0 | 13 Apr 2026 | 22 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 9.9 | 9 Jun 2026 | 26 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 5 May 2026 | 28 May 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 9.1 | 9.1 | 9.1 | 17 Dec 2024 | 17 Dec 2024 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.8 | 7.5 | 10.0 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.6 | 6.9 | 9.8 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.5 | 7.9 | 9.2 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.4 | 7.4 | 10.0 | 25 May 2026 | 25 May 2026 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 3 | 8.0 | 6.4 | 10.0 | 11 Jun 2025 | 19 Jan 2026 |
| Peptide WorldwideCASE #VI-2026-0217 | X | 1 | 7.7 | 7.7 | 7.7 | 3 Jul 2025 | 3 Jul 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 7.6 | 7.0 | 8.0 | 24 May 2026 | 24 May 2026 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 4 | 7.6 | 5.3 | 10.0 | 16 Mar 2025 | 23 May 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 3 | 6.9 | 6.1 | 7.4 | 13 Jun 2025 | 24 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 1 | 6.6 | 6.6 | 6.6 | 24 Apr 2025 | 24 Apr 2025 |
| Qingdao Hongshengda TradingCASE #VI-2026-0334 | X | 1 | 6.5 | 6.5 | 6.5 | 17 Dec 2024 | 17 Dec 2024 |
| NextechLabsCASE #VI-2026-0285 | X | 1 | 6.2 | 6.2 | 6.2 | 20 Jun 2025 | 20 Jun 2025 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 6.2 | 6.2 | 6.2 | 17 Dec 2024 | 17 Dec 2024 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 6.0 | 6.0 | 6.0 | 2 Jul 2025 | 2 Jul 2025 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 6.0 | 6.0 | 6.0 | 13 Feb 2025 | 13 Feb 2025 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 5.3 | 5.3 | 5.3 | 24 Apr 2025 | 24 Apr 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 2 | 4.9 | 4.8 | 5.0 | 21 May 2025 | 24 May 2026 |
| DeuschemCASE #VI-2026-0004 | X | 1 | 4.4 | 4.4 | 4.4 | 13 Jun 2025 | 13 Jun 2025 |
| HybiopeptidesCASE #VI-2026-0305 | X | 1 | 3.1 | 3.1 | 3.1 | 11 Jun 2025 | 11 Jun 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.6 | 0.6 | 0.6 | 25 Apr 2025 | 25 Apr 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.3 | 0.3 | 0.3 | 21 May 2025 | 21 May 2025 |
| HK Fat CatCASE #VI-2026-0376 | X | 1 | 0.0 | 0.0 | 0.0 | 14 Jan 2025 | 14 Jan 2025 |
Open any subject to view the batch-level evidence for Salbutamol alone.